Comparative Analysis of Metabolic Enzyme Profiles in Cancer vs. Normal Tissues

Thesis Abstract

Cancer alters cellular metabolism through reprogramming of enzyme activities that sustain malignant growth, invasion, and resistance to therapy; despite extensive profiling, comparative, cross-tissue analyses of metabolic enzyme spectra between tumor and adjacent normal tissues remain incompletely characterized across cancer types. This study aims to delineate differential metabolic enzyme profiles between cancerous and corresponding normal tissues to identify robust enzymatic signatures of malignancy and potential metabolic vulnerabilities. Specific objectives are to (1) quantify expression and activity levels of a panel of key metabolic enzymes involved in glycolysis (HK2, PFKP, PKM2), glutaminolysis (GLS), the tricarboxylic acid cycle (SDHA, FH), one-carbon metabolism (SHMT2, MTHFD2), and lipid synthesis (FASN, ACLY) across cancer and matched normal tissues; (2) assess tissue-specific versus pan-tumor patterns using multi-omics integration; (3) evaluate associations between enzyme profiles and clinicopathological features (tumor stage, grade, and receptor status where applicable); and (4) develop a composite metabolic encoder score predictive of tumor status. The theoretical framework integrates Warburg/Quinlan metabolic reprogramming and Hanahan–Weinberg hallmarks of cancer, supplemented by the ecological metabolic optima model to interpret cross-tissue enzyme network adaptations. A multicenter, cross-sectional design will be employed. The population comprises formalin-fixed paraffin-embedded and fresh-frozen tumor and adjacent normal tissue samples from 200 patients spanning four solid tumor types (breast, colorectal, lung, and prostate) collected from three tertiary hospitals. A stratified sampling approach will ensure equal representation of tumor stages I–IV and matched controls, targeting 100 tumor-normal pairs per cancer type. Data collection will utilize quantitative real-time PCR and Western blotting for mRNA and protein abundance, complemented by enzymatic activity assays and targeted metabolomics (LC-MS/MS) to measure substrate/product fluxes and cofactor levels. Immunohistochemistry will provide spatial context for enzyme expression, while RNA-Seq will enable broader pathway-level analyses. Instrument validity will be established via incorporation of standardized reference controls, spike-in standards for metabolomics, and inter-laboratory calibration. Data quality will be monitored through duplicate measurements, randomization, and blinded analysis. Statistical analyses will entail descriptive statistics to summarize enzyme expression and activity, followed by paired t-tests or Wilcoxon signed-rank tests for tumor-normal comparisons. Multivariate analyses will utilize mixed-effects models to account for within-patient pairing and between-tissue variability. ANOVA and post-hoc tests will compare across cancer types, while principal component analysis and partial least squares discriminant analysis will reduce dimensionality and identify latent enzymatic signatures. Regression analyses will explore associations between enzyme profiles and clinicopathological features, and receiver operating characteristic (ROC) curves will evaluate the diagnostic performance of the metabolic encoder score. A systems biology approach will integrate transcriptomic, proteomic, and metabolomic data to reconstruct tissue-specific metabolic networks and identify key regulatory nodes using network topology metrics and flux balance analysis where feasible. Expected findings include robust upregulation of glycolytic enzymes and glutaminolysis components in tumor tissues, with concordant increases in related lipid synthesis and one-carbon metabolism enzymes, illustrating a cohesive tumor metabolic program. Variability in enzyme signatures is anticipated across cancer types, yet a core pancancer set of enzymes (e.g., HK2, PKM2, GLS, FASN) is expected to discriminate tumor from normal tissue with high accuracy. Strong associations between elevated enzyme activity and adverse clinicopathological features, particularly higher grade and advanced stage, are hypothesized. The study will contribute to knowledge by providing a validated cross-tumor metabolic enzyme signature, offering mechanistic insight into tissue-specific metabolic adaptations and identifying candidate metabolic targets for therapy or biomarker development. In conclusion, the research is expected to demonstrate that cancer imposes a coordinated shift in metabolic enzyme profiles across diverse tissues, revealing a reproducible core signature with tissue-specific refinements. Recommendations will include exploring targeted inhibitors against pivotal enzymes identified in the pancancer core and validating the metabolic encoder score in prospective cohorts to support precision oncology strategies.